新型隐球菌感染合并2型糖尿病个体化药学监护一例  

Individualized pharmaceutical care on a Cryptococcus neoformans infection patient complicated with type 2 diabetes

作　　者：孙莎莎 张凡 朱曼[1] SUN Sha-sha;ZHANG Fan;ZHU Man(Department of Pharmacy,Medical Supplies Center of Chinese PLA General Hospital,Beijing 100853,China;Department of Clinical Pharmacy,Liaocheng Infectious Disease Hospital,Shandong Liaocheng 252000,China;Department of Clinical Pharmacy,the Third Affiliated Hospital of Xinxiang Medical University,Henan Xinxiang 453000,China)

机构地区：[1]解放军总医院医疗保障中心药剂科,北京100853 [2]聊城市传染病医院临床药学研究室,山东聊城252000 [3]新乡医学院第三附属医院临床药学室,河南新乡453000

出　　处：《临床药物治疗杂志》2023年第9期84-86,共3页Clinical Medication Journal

摘　　要：本文报告1例55岁患者,因咳嗽3个月,间断发热2个月入院,入院后诊断为肺隐球菌感染、肝功能不全、2型糖尿病,给予伏立康唑抗真菌治疗,动态调整人胰岛素降糖治疗。对患者多次伏立康唑血药谷浓度低于有效浓度范围及其CYP2C19基因检测,临床药师进行个体化药学监护,治疗期间患者病情转归良好出院。A 55-year-old patient was admitted due to cough for 3 months and intermittent fever for 2 months.After ad⁃mission,the patient was diagnosed as cryptococcus neoformans pneumonia,hepatic insufficiency,and type 2 diabetes and given voriconazole for antifungal therapy and dynamic adjustment of insulin injection for hypoglycemic therapy.The clinical pharmacist carried out individualized pharmaceutical care against the fact that the patient's plasma trough concentration of vori⁃conazole was lower than the effective concentration threshold and the CYP2C19 gene report.The patient's condition improved during the treatment period and finally was discharged from the hospital.

关 键 词：新型隐球菌 伏立康唑 药学监护 

分 类 号：R969.3[医药卫生—药理学]